肝硬化难治性腹水患者行特利加压素搭配前列地尔治疗的疗效.docVIP

肝硬化难治性腹水患者行特利加压素搭配前列地尔治疗的疗效 　　【摘要】 目的 探讨肝硬化难治性腹水患者行特利加压素搭配前列地尔治疗的临床效果。方法 90例肝硬化难治性腹水患者作为研究对象， 将其随机分为观察组和对照组， 各45例。对照组给予单纯前列地尔治疗， 观察组在对照组基础上给予特利加压素搭配治疗。统计两组患者的临床治疗效果， 治疗前后血肌酐、24 h尿量以及白蛋白水平变化。结果 观察组临床治疗总有效率为80.00%， 明显高于对照组的95.56%， 差异有统计学意义（P0.05）。治疗后两组血肌酐、24 h尿量以及白蛋白水平均有所改善， 差异有统计学意义（P0.05）；观察组血肌酐水平显著低于对照组， 24 h尿量以及白蛋白水平明显高于对照组， 差异有统计学意义（P0.05）。结论 肝硬化难治性腹水行特利加压素搭配前列地尔治疗效果良好， 可有效改善患者肾功能， 缓解临床症状， 具有一定的参考价值。 　　【关键词】 肝硬化；难治性腹水；特利加压素；前列地尔 　　DOI：10.14163/j.cnki.11-5547/r.2017.18.058 　　【Abstract】 Objective To explore the clinical effect of liver cirrhosis refractory ascites patients treated with terlipressin and alprostadil. Methods A total of 90 liver cirrhosis refractory ascites patients as study subjects were randomly divided into observation group and control group， with 45 cases in each group. The control group received alprostadil alone for treatment， and the observation group received terlipressin on the basis of the control group. Statistical analysis were made on clinical effects， changes in serum creatinine， 24 h urine volume， and albumin levels between two groups. Results The observation group had obviously higher total effective rate of clinical treatment as 80.00% than 95.56% in the control group， and the difference had statistical significance （P0.05）. After treatment， both groups had improved serum creatinine， 24 h urine volume， and albumin levels， and the difference had statistical significance （P0.05）. The observation group had obviously lower serum creatinine level than the control group， and obviously higher 24 h urine volume and albumin levels than the control group （P0.05）. Conclusion Combination of terlipressin and alprostadil shows good therapeutic effect in the treatment of liver cirrhosis refractory ascites， and it can effectively improve the renal function of patients and relieve the clinical symptoms. This method contains certain reference value. 　　【Key words】 Liver cirrhosis； Refractory ascites； Terlipressin； Alprostadil 　　肝硬化?y治性腹水病情严重， 发病